ArticleThe pharmacogenomics journal2013
COMT Val158Met modulates subjective responses to intravenous nicotine and cognitive performance in abstinent smokers.
Article in The pharmacogenomics journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- COMT polymorphism modulates the resting-state EEG alpha oscillatory response to acute nicotine in male non-smokers.Genes, brain, and behavior · 2015Trial
- Examining racial differences in smoking outcomes among smokers enrolled in an intravenous nicotine infusion study.Addictive behaviors · 2023Article
- Catechol-O-Methyltransferase Effects on Smoking: A Review and Proof of Concept of Sex-Sensitive Effects.Current behavioral neuroscience reports · 2022Article
- Subjective reward processing and catechol-Frontiers in psychiatry · 2022Article
- Biochemical, demographic, and self-reported tobacco-related predictors of the acute heart rate response to nicotine in smokers.Pharmacology, biochemistry, and behavior · 2018Article
- Addiction and Dopamine: Sex Differences and Insights from Studies of Smoking.Current opinion in behavioral sciences · 2018Article
- Cognitive Effects of Nicotine: Recent Progress.Current neuropharmacology · 2018Review
- A protocadherin gene cluster regulatory variant is associated with nicotine withdrawal and the urge to smoke.Molecular psychiatry · 2017Article
- An initial investigation of associations between dopamine-linked genetic variation and smoking motives in African Americans.Pharmacology, biochemistry, and behavior · 2015Article
- A CHRNA5 Smoking Risk Variant Decreases the Aversive Effects of Nicotine in Humans.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Article
- Gender Considerations in Addiction: Implications for Treatment.Current treatment options in psychiatry · 2015Article
- FKBP5 variation is associated with the acute and chronic effects of nicotine.The pharmacogenomics journal · 2015Article
- Pharmacogenetics of nicotine addiction: role of dopamine.Pharmacogenomics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The catechol-O-methyltransferase (COMT) Val158Met polymorphism may be a risk factor for nicotine addiction. This study examined the influence of the COMT Val158Met polymorphism on subjective, physiological and cognitive effects of intravenous (IV) nicotine use in African Americans (AAs; n=56) and European Americans (EAs; n=68) smokers. Overnight abstinent smokers received saline followed by 0.5 and 1.0 mg per 70 kg doses of nicotine, administered 30 min apart. Smokers with valine (Val)/Val genotype, compared with methionine (Met) carriers, had greater negative subjective effects from IV nicotine and had more severe withdrawal severity following overnight abstinence from smoking. Women with Val/Val genotype reported greater difficulty concentrating and irritability than men with Val/Val or Met carrier genotypes. The Val/Val genotype was associated with better performance on the math task and in AA smokers it was associated with greater systolic blood pressure. These results support the rationale of pharmacologically inhibiting COMT to aid with smoking cessation among Val/Val genotype smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.